{"nctId":"NCT01022424","briefTitle":"A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]","startDateStruct":{"date":"2009-11"},"conditions":["Autosomal Dominant Polycystic Kidney Disease"],"count":13,"armGroups":[{"label":"OPC-41061","type":"EXPERIMENTAL","interventionNames":["Drug: OPC-41061"]}],"interventions":[{"name":"OPC-41061","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who completed 3-year repeated administrations and the follow-up observation or those who were withdrawn from the study due to reasons other than occurrence of adverse events (based on the judgment of either the subject or the investigator/subinvestigator) in the preceding study (156-05-002)\n* Patients in whom adverse events occurring in study 156-05-002 were resolved or became stable and do not require further follow-up.\n\nExclusion Criteria:\n\n* Patients with eGFR of less than 15 mL/min/1.73 m2\n* Patients with any of the following complications:\n\n  * Uncontrolled hypertension\n  * Serious cardiovascular disease (eg. heart failure) or hepatic disease (eg. cirrhosis)\n* Patients with any of the following complications or history thereof:\n\n  * Clinically significant drug allergies (anaphylaxis) or hypersensitivity (especially, hypersensitivity to benzazepine derivatives or suspected hypersensitivity\n  * Inability to personally give consent due to a mental illness","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Total Kidney Volume","description":"Individual subject data on the volumes of the total kidney volume (sum of the volumes of the left and right kidneys) measured by magnetic resonance imaging or computed tomography during trial period.\n\nRepeated oral administration at doses of 15 mg twice daily (morning and evening) until approval of the revised protocol (Edition 4.0) by the IRB of each trial site.\n\nNumber of participants analyzed at each time point represents number of participants with data at the specified time point. Patients who were withdrawn from trial or have no appropriate data (e.g., interruption of medication, protocol deviation, etc.) are excluded.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1428","spread":null},{"groupId":"OG001","value":"1675","spread":null},{"groupId":"OG002","value":"1728","spread":null},{"groupId":"OG003","value":"1775","spread":null},{"groupId":"OG004","value":"1901","spread":null}]}]}]},{"type":"PRIMARY","title":"Renal Function Test (eGFR)","description":"Individual subject data on eGFR (estimated glomerular filtration rate calculated by Japanese eGFR equation) during trial period.\n\nNumber of participants analyzed at each time point represents number of participants with data at the specified time point. Patients who were withdrawn from trial or have no appropriate data (e.g., interruption of medication, protocol deviation, etc.) are excluded.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.0","spread":null},{"groupId":"OG001","value":"60.0","spread":null},{"groupId":"OG002","value":"54.0","spread":null},{"groupId":"OG003","value":"50.5","spread":null},{"groupId":"OG004","value":"51.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":13},"commonTop":["Nasopharyngitis","Blood antidiuretic hormone increased","Hypertension","Thirst","Back pain"]}}}